SAN FRANCISCO (AP) _ Nektar Therapeutics (NKTR) on Thursday reported a loss of $159.1 million in its second quarter.

The San Francisco-based company said it had a loss of 85 cents per share.

The results beat Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of $1.01 per share.

The biopharmaceutical company posted revenue of $21.6 million in the period, which fell short of Street forecasts. Seven analysts surveyed by Zacks expected $23.2 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NKTR at https://www.zacks.com/ap/NKTR

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News